Viral vectors and the use of the same for gene therapy

Details Viral vectors and the use of the same for gene therapy Viral vectors and the use of the same for gene therapy

2003-10-10

2011-11-29

Bertoglio, Valarie (Department: 1632)

Chemistry: molecular biology and microbiology

Vector, per se

C514S04400A, C536S023100

Reexamination Certificate

active

08067227

ABSTRACT:
The invention relates to viral vectors comprising nucleic acid sequences coding for single chain interleukin-12 (single chain IL-12 or scIL12) and a costimulator protein, and to the use of vectors for gene therapy, especially for the treatment of tumors. The invention further relates to adenoviral vectors containing nucleic acid sequences having a sequence homology of at least 90% in relation to the sequence displayed in FIGS.19and20(IL-12), in FIG.21(4-1BB ligand) and in FIG.22(IL-2) and optionally also one of the sequences displayed in FIG.23A (B7-1) or23B (B7-2).

REFERENCES:
patent: 5756085 (1998-05-01), Sykes et al.
patent: 2002/0018767 (2002-02-01), Kim et al.
patent: WO 00/41508 (2000-07-01), None
patent: WO 02/27007 (2002-04-01), None
Wen et al., 2001, Cancer Gene Therapy, vol. 8, pp. 361-370.
Wilson JM, 1996, Molecular Med., vol. 334(18), pp. 1185-1187.
Martinet et al., 2000, J. NCI, vol. 92(11), pp. 931-936.
Vinay et al.,1998, Seminars in Immunology, vol. 10, pp. 481-489.
Yokota et al., 1985, PNAS, vol. 82, pp. 68-72.
Martinez-Salas et al., Current Opinion in Biotechnology 1999, vol. 10, pp. 458-464.
Hennecke et al., 2001, Nucleic Acid Res., vol. 29(16), pp. 3327-3334.
Addison et al., “Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors”,Gene Therapy, vol. 5, pp. 1400-1409 (1998).
Barajas et al., “Gene Therapy of Orthotopic Hepatocellular Carcinoma in Rats Using Adenovirus Coding for Interleukin 12”,Hepatology, vol. 33, No. 1, pp. 52-61 (2001).
Brunda et al., “Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors”,J. Exp. Med., vol. 178, pp. 1223-1230 (1993).
Carroll et al., “Construction and Characterization of a Triple-Recombinant Vaccinia Virus Encoding B7-1, Interleukin 12, and a Model Tumor Antigen”,Journal of the National Cancer Institute, vol. 90, No. 24, pp. 1881-1887 (1998).
Cohen, “IL-12 Deaths: Explanation and a Puzzle”,Science, vol. 270, pp. 908 (1995).
Emtage et al., “A Double Recombinant Adenovirus Expressing the Costimulatory Molecule B7-1 (Murine) and Human IL-2 Induces Complete Tumor Regression in a Murine Breast Adenocarcinoma Model”,The Journal of Immunology, vol. 160, pp. 2531-2538 (1998).
Gillis et al., “T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity”,The Journal of Immunology, vol. 120, No. 6, pp. 2027-2032 (1978).
Guinn et al., “4-1BBL Cooperates with B7-1 and B7-2 in Converting a B Cell Lymphoma Cell Line into a Long-Lasting Antitumor Vaccine”,The Journal of Immunology, vol. 162, pp. 5003-5010 (1999).
Gyorffy et al., “Combined Treatment of a Murine Breast Cancer Model with Type 5 Adenovirus Vectors Expressing Murine Angiostatin and IL-12: A Role for Combined Anti-Angiogenesis and Immunotherapy”,The Journal of Immunology, vol. 166, pp. 6212-6217 (2001).
Hock et al., “Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ”,Proc. Natl. Acad. Sci. USA, vol. 90, pp. 2774-2778 (1993).
International Search Report of PCT/EP03/11252, dated Apr. 16, 2004.
Kwon et al., “4-1BB: Still in the Midst of Darkness”,Mol. Cells, vol. 10, No. 2, pp. 119-126 (2000).
Lieschke et al., “Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo”,Nature Biotechnology, vol. 15, pp. 35-40 (1997).
Llovet et al., “Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials”,Hepatology, vol. 29, pp. 62-67 (1999).
Lotze et al., “Cytokine Gene Therapy of Cancer Using Interleukin-12: Murine and Clinical Trials”,Annals New York Academy of Sciences, vol. 795, pp. 440-454 (1997).
Mah et al., “Virus-Based Gene Delivery Systems”,Clin. Pharmacokinet, vol. 41, No. 12, pp. 901-911 (2002).
Martinet et al., “Immunomodulatory Gene Therapy with Interleukin 12 and 4-1BB Ligand: Long-Term Remission of Liver Metastases in a Mouse Model”,Journal of the National Cancer Institute, vol. 92, No. 11, pp. 931-936 (2000).
Martinet et al., “T cell activation with systematic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer”,Gene Therapy, vol. 9, pp. 786-792 (2002).
Mazzolini et al., “Regression of cancer and induction of antitumor immunity by intratumoral injection of colon adenovirus expressing interleukin-12”,Cancer Gene Therapy, vol. 6, No. 6, pp. 514-522 (1999).
Melero et al., “IL-12 gene therapy for cancer: in synergy with other immunotherapies”,Trends in Immunology, vol. 22, No. 3, pp. 113-115 (2001).
Nicklin and Baker, “Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy”,Current Gene Therapy, vol. 2, pp. 273-293 (2002).
Putzer et al., “Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression”,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 10889-10894 (1997).
Ruiz et al., “Gene Therapy of Hepatocellular Carcinoma”,Digestive Diseases, vol. 19, pp. 324-332 (2001).
Sethi et al., “Postexposure prophylaxis against prion disease with a stimulator of innate immunity”,The Lancet, vol. 360, pp. 229-230 (2002).
van der Meide et al., “Stimulation of both humoral and cellular immune responses to HIV-1 gp120 by interleukin-12 inRhesus macaques”, Vaccine, vol. 20, pp. 2296-2302 (2002).
van der Poel el al., “Epidermal Growth Factor Receptor Targeting of Replication Competent Adenovirus Enhances Cytotoxicity in Bladder Cancer”,The Journal of Urology, vol. 168, pp. 266-272 (2002).
Vinay and Kwon, “Role of 4-1BB in immune responses”,Immunology, vol. 10, pp. 481-489 (1998).
Yoon et al., “Selectively Replicating Adenoviruses for Oncolytic Therapy”,Current Cancer Drug Targets, vol. 1, No. 2, pp. 85-107 (2001).
Anderson et al., “Construction and Biological Characterization of an Interleukin-12 Fusion Protein (Flexi-12): Delivery to Acute Myeloid Leukemic Blasts Using Adeno-Associated Virus”,Human Gene Therapy, 8:1125-1135 (1997).
Gillies et al., “Bi-Functional Cytokine Fusion Proteins for Gene Therapy and Antibody-Targeted Treatment of Cancer”,Cancer Immunol Immunother., 8:449-460 (2002) (Abstract).
Tan et al., “4-1BB Ligand, a Member of the TNF Family, is Important for the Generation of Antiviral CD8 T Cell Responses”,The Journal of Immunology, pp. 4859-4868 (1999).

Affiliated with

Also associated with

Rating

Viral vectors and the use of the same for gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral vectors and the use of the same for gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vectors and the use of the same for gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313192